Perspective Therapeutics, Inc. (CATX)
(Delayed Data from AMEX)
$13.70 USD
+0.08 (0.59%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $13.69 -0.01 (-0.07%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Perspective Therapeutics (CATX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$22.25 | $29.00 | $17.00 | 63.36% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Perspective Therapeutics comes to $22.25. The forecasts range from a low of $17.00 to a high of $29.00. The average price target represents an increase of 63.36% from the last closing price of $13.62.
Analyst Price Targets (4 )
Broker Rating
Perspective Therapeutics currently has an average brokerage recommendation (ABR) of 1.17 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.20 a month ago based on five recommendations.
Of the six recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 83.33% and 16.67% of all recommendations. A month ago, Strong Buy made up 80%, while Buy represented 20%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 4 | 4 | 4 | 2 |
Buy | 1 | 1 | 1 | 1 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.17 | 1.20 | 1.20 | 1.20 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/18/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
6/18/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/14/2024 | Not Identified | Not Identified | Not Available | Moderate Buy |
5/6/2024 | LifeSci Capital | Anshul Dhankher | Not Available | Strong Buy |
4/9/2024 | B. Riley Securities | Yuan Zhi | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.17 |
ABR (Last week) | 1.20 |
# of Recs in ABR | 6 |
Average Target Price | $22.60 |
LT Growth Rate | 13.50% |
Industry | Medical - Drugs |
Industry Rank by ABR | 97 of 252 |
Current Quarter EPS Est: | -0.21 |